These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 18832928

  • 1. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E, Cornelissen JJ.
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [Abstract] [Full Text] [Related]

  • 2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 3. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 4. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
    McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL.
    Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
    [Abstract] [Full Text] [Related]

  • 5. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 6. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
    Okamura T, Kishimoto T, Inoue M, Honda M, Yamashita N, Wakiguchi H, Yagita M, Hosoi G, Sako M, Yasui M, Yagi K, Kawa K.
    Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K.
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, Scieux C, Devergie A, Socié G, Ribaud P, Adès L, Ferry C, Gluckman E, Charron D, Esperou H, Toubert A, Moins-Teisserenc H.
    Transplantation; 2004 Jan 15; 77(1):76-84. PubMed ID: 14724439
    [Abstract] [Full Text] [Related]

  • 9. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Jan 15; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 10. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens.
    Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E.
    J Clin Microbiol; 2005 Jul 15; 43(7):3540-3. PubMed ID: 16000501
    [Abstract] [Full Text] [Related]

  • 11. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.
    Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekker AW, Verdonck LF.
    Bone Marrow Transplant; 2002 Feb 15; 29(4):335-9. PubMed ID: 11896431
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM, Crawford DH.
    Blood Rev; 2004 Sep 15; 18(3):193-209. PubMed ID: 15183903
    [Abstract] [Full Text] [Related]

  • 13. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D.
    Transplantation; 2009 Apr 27; 87(8):1240-5. PubMed ID: 19384173
    [Abstract] [Full Text] [Related]

  • 14. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.
    Pediatr Blood Cancer; 2006 Aug 27; 47(2):200-5. PubMed ID: 16206207
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults.
    Suzuki K, Ohshima K, Karube K, Suzumiya J, Ohga S, Ishihara S, Tamura K, Kikuchi M.
    Int J Oncol; 2004 May 27; 24(5):1165-74. PubMed ID: 15067338
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 17. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ.
    Blood; 2002 Jun 15; 99(12):4364-9. PubMed ID: 12036863
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
    Chiang KY, Hazlett LJ, Godder KT, Abhyankar SH, Christiansen NP, van Rhee F, Lee CG, Bridges K, Parrish RS, Henslee-Downey PJ.
    Bone Marrow Transplant; 2001 Dec 15; 28(12):1117-23. PubMed ID: 11803352
    [Abstract] [Full Text] [Related]

  • 19. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.
    Sirvent-Von Bueltzingsloewen A, Morand P, Buisson M, Souillet G, Chambost H, Bosson JL, Bordigoni P.
    Bone Marrow Transplant; 2002 Jan 15; 29(1):21-8. PubMed ID: 11840140
    [Abstract] [Full Text] [Related]

  • 20. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 15; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.